Overview of multi-omics research in gout
Received date: 2023-04-03
Revised date: 2023-06-13
Online published: 2023-06-28
Supported by
National Key Research and Development Program of China(2022YFC2503304);National Natural Science Foundation of China(82220108015)
Gout is a self-limiting inflammation disease triggered by deposition of monosodium urate with a variety of comorbidities. With the improvement of living standards, the global incidence of gout is increasing year by year, which seriously affects people's health. As an effective tool to study diseases, omics technology has been widely used to discover potential biomarkers and risk factors of gout. The identified variation sites or different-expressed products provide different dimensions of insights for the study of the pathogenesis and disease progression of gout. In this review, the application and research results of multi-omics technology in gout were analyzed and summarized through PubMed literature retrieval. Meanwhile, the recent research progress of multi-omics technology in the field of gout was reviewed to understand the specific changes of gout patients at different molecular levels, and to provide ideas and directions for further research on gout in the future.
Key words： gout; genomics; epigenomics; transcriptomics; proteomics
Wenrui Shi, Hongzhu Qu, Xiangdong Fang . Overview of multi-omics research in gout[J]. Hereditas(Beijing), 2023 , 45(8) : 643 -657 . DOI: 10.16288/j.yczz.23-086
| [1] | Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nat Rev Dis Primers, 2019, 5(1): 69. |
| [2] | Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine, 2011, 78(1): 35-40. |
| [3] | Kuo CF, Grainge MJ, Zhang WY, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol, 2015, 11(11): 649-662. |
| [4] | Butler F, Alghubayshi A, Roman Y. The epidemiology and genetics of hyperuricemia and gout across major racial groups: a literature review and population genetics secondary database analysis. J Pers Med, 2021, 11(3): 231. |
| [5] | Punzi L, Scanu A, Galozzi P, Luisetto R, Spinella P, Scire CA, Oliviero F. One year in review 2020: gout. Clin Exp Rheumatol, 2020, 38(5): 807-821. |
| [6] | Zhao M, Chen T, Huang ZG, Zhong QA.Disease burden of gout in China, 1990—2019. Mod Prev Med, 2021, 48(21): 3974-3978. |
| [6] | 赵敏, 陈婷, 黄振光, 钟秋安. 1990—2019年中国痛风疾病负担研究. 现代预防医学, 2021, 48(21): 3974-3978. |
| [7] | Song J, Jin CY, Shan ZY, Teng WP, Li J. Prevalence and risk factors of hyperuricemia and gout: a cross-sectional survey from 31 provinces in mainland China. J Transl Int Med, 2022, 10(2): 134-145. |
| [8] | Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CNA, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu XH, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, Mckeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet, 2008, 40(4): 437-442. |
| [9] | Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet, 2021, 397(10287): 1843-1855. |
| [10] | Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford), 2013, 52(1): 34-44. |
| [11] | Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis, 2010, 68(3): 199-203. |
| [12] | Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A, March L.The global burden of gout: estimates from the global burden of disease 2010 study. Ann Rheum Dis, 2014, 73(8): 1470-1476. |
| [13] | Narang RK, Dalbeth N. Pathophysiology of gout. Semin Nephrol, 2020, 40(6): 550-563. |
| [14] | Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol, 2012, 8(10): 610-621. |
| [15] | Cadzow M, Merriman TR, Dalbeth N. Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank. Arthritis Res Ther, 2017, 19(1): 181. |
| [16] | Xu PZ, Liu P, Zhou CM, Shi Y, Wu QP, Yang YT, Li GY, Hu GL, Guo XQ. A multi-omics study of chicken infected by nephropathogenic infectious bronchitis virus. Viruses, 2019, 11(11): 1070. |
| [17] | Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights, 2020, 14: 1177932219899051. |
| [18] | Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol, 2019, 25(30): 4199-4212. |
| [19] | Ivanova O, Richards LB, Vijverberg SJ, Neerincx AH, Sinha A, Sterk PJ, Maitland-Van der Zee AH. What did we learn from multiple omics studies in asthma? Allergy, 2019, 74(11): 2129-2145. |
| [20] | Zheng M, Ma JW. Research progress in the genetics of hyperuricaemia and gout. Hereditas (Beijing), 2016, 38(4): 300-313. |
| [20] | 郑敏, 麻骏武. 高尿酸血症和痛风的遗传学研究进展. 遗传, 2016, 38(4): 300-313. |
| [21] | Alghubayshi A, Edelman A, Alrajeh K, Roman Y. Genetic assessment of hyperuricemia and gout in Asian, Native Hawaiian, and Pacific Islander subgroups of pregnant women: biospecimens repository cross-sectional study. BMC Rheumatol, 2022, 6(1): 1. |
| [22] | Tin A, Marten J, Halperin Kuhns VL, Li Y, Wuttke M, Kirsten H, Sieber KB, Qiu CX, Gorski M, Yu Z, Giri A, Sveinbjornsson G, Li M, Chu AY, Hoppmann A, O'Connor LJ, Prins B, Nutile T, Noce D, Akiyama M, Cocca M, Ghasemi S, van der Most PJ, Horn K, Xu YZ, Fuchsberger C, Sedaghat S, Afaq S, Amin N, ?rnl?v J, Bakker SJL, Bansal N, Baptista D, Bergmann S, Biggs ML, Biino G, Boerwinkle E, Bottinger EP, Boutin TS, Brumat M, Burkhardt R, Campana E, Campbell A, Campbell H, Carroll RJ, Catamo E, Chambers JC, Ciullo M, Concas MP, Coresh J, Corre T, Cusi D, Felicita SC, de Borst MH, De Grandi A, de Mutsert R, de Vries APJ, Delgado G, Demirkan A, Devuyst O, Dittrich K, Eckardt KU, Ehret G, Endlich K, Evans MK, Gansevoort RT, Gasparini P, Giedraitis V, Gieger C, Girotto G, G?gele M, Gordon SD, Gudbjartsson DF, Gudnason V, German Chronic Kidney Disease Stud, Haller T, Hamet P, Harris TB, Hayward C, Hicks AA, Hofer E, Holm H, Huang W, Hutri-K?h?nen N, Hwang SJ, Ikram MA, Lewis RM, Ingelsson E, Jakobsdottir J, Jonsdottir I, Jonsson H, Joshi PK, Josyula NS, Jung B, K?h?nen M, Kamatani Y, Kanai M, Kerr SM, Kiess W, Kleber ME, Koenig W, Kooner JS, K?rner A, Kovacs P, Kr?mer BK, Kronenberg F, Kubo M, Kühnel B, La Bianca M, Lange LA, Lehne B, Lehtimaki T, Lifelines Cohort Study, Liu J, Loeffler M, Loos RJF, Lyytik?inen LP, Magi R, Mahajan A, Martin NG, M?rz W, Mascalzoni D, Matsuda K, Meisinger C, Meitinger T, Metspalu A, Milaneschi Y, V. A. Million Veteran Program, O'Donnell CJ, Wilson OD, Gaziano JM, Mishra PP, Mohlke KL, Mononen N, Montgomery GW, Mook-Kanamori DO, Müller-Nurasyid M, Nadkarni GN, Nalls MA, Nauck M, Nikus K, Ning BT, Nolte IM, Noordam R, O'Connell JR, Olafsson I, Padmanabhan S, Penninx BWJH, Perls T, Peters A, Pirastu M, Pirastu N, Pistis G, Polasek O, Ponte B, Porteous DJ, Poulain T, Preuss MH, Rabelink TJ, Raffield LM, Raitakari OT, Rettig R, Rheinberger M, Rice KM, Rizzi F, Robino A, Rudan I, Krajcoviechova A, Cifkova R, Rueedi R, Ruggiero D, Ryan KA, Saba Y, Salvi E, Schmidt H, Schmidt R, Shaffer CM, Smith AV, Smith BH, Spracklen CN, Strauch K, Stumvoll M, Sulem P, Tajuddin SM, Teren A, Thiery J, Thio CHL, Thorsteinsdottir U, Toniolo D, T?njes A, Tremblay J, Uitterlinden AG, Vaccargiu S, van der Harst P, van Duijn CM, Verweij N, V?lker U, Vollenweider P, Waeber G, Waldenberger M, Whitfield JB, Wild SH, Wilson JF, Yang Q, Zhang WH, Zonderman AB, Bochud M, Wilson JG, Pendergrass SA, Ho K, Parsa A, Pramstaller PP, Psaty BM, B?ger CA, Snieder H, Butterworth AS, Okada Y, Edwards TL, Stefansson K, Susztak K, Scholz M, Heid IM, Hung AM, Teumer A, Pattaro C, Woodward OM, Vitart V, K?ttgen A. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet, 2019, 51(10): 1459-1474. |
| [23] | Sandoval-Plata G, Morgan K, Abhishek A. Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank. Ann Rheum Dis, 2021, 80(9): 1220-1226. |
| [24] | Jing JJ, Ekici AB, Sitter T, Eckardt KU, Schaeffner E, Li Y, Kronenberg F, K?ttgen A, Schultheiss UT. Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease. Sci Rep, 2018, 8(1): 13184. |
| [25] | Dong Z, Zhou JR, Xu X, Jiang S, Li Y, Zhao DB, Yang CD, Ma YY, Wang Y, He HJ, Ji HD, Zhang J, Yuan ZY, Yang YJ, Wang XF, Pang YF, Jin L, Zou HJ, Wang JC. Genetic variants in two pathways influence serum urate levels and gout risk: a systematic pathway analysis. Sci Rep, 2018, 8(1): 3848. |
| [26] | Kawamura Y, Nakaoka H, Nakayama A, Okada Y, Yamamoto K, Higashino T, Sakiyama M, Shimizu T, Ooyama H, Ooyama K, Nagase M, Hidaka Y, Shirahama Y, Hosomichi K, Nishida Y, Shimoshikiryo I, Hishida A, Katsuura-Kamano S, Shimizu S, Kawaguchi M, Uemura H, Ibusuki R, Hara M, Naito M, Takao M, Nakajima M, Iwasawa S, Nakashima H, Ohnaka K, Nakamura T, Stiburkova B, Merriman TR, Nakatochi M, Ichihara S, Yokota M, Takada T, Saitoh T, Kamatani Y, Takahashi A, Arisawa K, Takezaki T, Tanaka K, Wakai K, Kubo M, Hosoya T, Ichida K, Inoue I, Shinomiya N, Matsuo H. Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout. Ann Rheum Dis, 2019, 78(10): 1430-1437. |
| [27] | Kawaguchi M, Nakayama A, Aoyagi Y, Nakamura T, Shimizu S, Kawamura Y, Takao M, Tamura T, Hishida A, Nagayoshi M, Nagase M, Ooyama K, Ooyama H, Shinomiya N, Matsuo H. Both variants of A1CF and BAZ1B genes are associated with gout susceptibility: a replication study and meta-analysis in a Japanese population. Hum Cell, 2021, 34(2): 293-299. |
| [28] | Lee MTG, Hsu TC, Chen SC, Lee YC, Kuo PH, Yang JH, Chang HH, Lee CC. Integrative genome-wide association studies of eQTL and GWAS data for gout disease susceptibility. Sci Rep, 2019, 9(1): 4981. |
| [29] | Chang SJ, Toyoda Y, Kawamura Y, Nakamura T, Nakatochi M, Nakayama A, Liao WT, Shimizu S, Takada T, Takeuchi K, Wakai K, Shi YY, Shinomiya N, Chen CJ, Li CG, Okada Y, Ichida K, Matsuo H, for Japan Gout Genomics Consortium (Japan Gout). A meta-analysis of genome-wide association studies using Japanese and Taiwanese has revealed novel loci associated with gout susceptibility. Hum Cell, 2022, 35(2): 767-770. |
| [30] | Nakayama A, Nakatochi M, Kawamura Y, Yamamoto K, Nakaoka H, Shimizu S, Higashino T, Koyama T, Hishida A, Kuriki K, Watanabe M, Shimizu T, Ooyama K, Ooyama H, Nagase M, Hidaka Y, Matsui D, Tamura T, Nishiyama T, Shimanoe C, Katsuura-Kamano S, Takashima N, Shirai Y, Kawaguchi M, Takao M, Sugiyama R, Takada Y, Nakamura T, Nakashima H, Tsunoda M, Danjoh I, Hozawa A, Hosomichi K, Toyoda Y, Kubota Y, Takada T, Suzuki H, Stiburkova B, Major TJ, Merriman TR, Kuriyama N, Mikami H, Takezaki T, Matsuo K, Suzuki S, Hosoya T, Kamatani Y, Kubo M, Ichida K, Wakai K, Inoue I, Okada Y, Shinomiya N, Matsuo H, Japan Gout Genomics Consortium (Japan Gout). Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients. Ann Rheum Dis, 2020, 79(5): 657-665. |
| [31] | Nakayama A, Nakaoka H, Yamamoto K, Sakiyama M, Shaukat A, Toyoda Y, Okada Y, Kamatani Y, Nakamura T, Takada T, Inoue K, Yasujima T, Yuasa H, Shirahama Y, Nakashima H, Shimizu S, Higashino T, Kawamura Y, Ogata H, Kawaguchi M, Ohkawa Y, Danjoh I, Tokumasu A, Ooyama K, Ito T, Kondo T, Wakai K, Stiburkova B, Pavelka K, Stamp LK, Dalbeth N, Eurogout Consortium, Sakurai Y, Suzuki H, Hosoyamada M, Fujimori S, Yokoo T, Hosoya T, Inoue I, Takahashi A, Kubo M, Ooyama H, Shimizu T, Ichida K, Shinomiya N, Merriman TR, Matsuo H, Eurogout Consortium. GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann Rheum Dis, 2017, 76(5): 869-877. |
| [32] | Toyoda Y, Nakayama A, Nakatochi M, Kawamura Y, Nakaoka H, Yamamoto K, Shimizu S, Ooyama H, Ooyama K, Shimizu T, Nagase M, Hidaka Y, Ichida K, Inoue I, Shinomiya N, Matsuo H, Japan Gout Genomics Consortium (Japan Gout). Genome-wide meta-analysis between renal overload type and renal underexcretion type of clinically defined gout in Japanese populations. Mol Genet Metab, 2022, 136(3): 186-189. |
| [33] | Eun Y, Kim IY, Han K, Lee KN, Lee DY, Shin DW, Kang S, Lee S, Cha HS, Koh EM, Lee J, Kim H. Association between female reproductive factors and gout: a nationwide population-based cohort study of 1 million postmenopausal women. Arthritis Res Ther, 2021, 23(1): 304. |
| [34] | Lin CY, Chang YS, Liu TY, Huang CM, Chung CC, Chen YC, Tsai FJ, Chang JG, Chang SJ. Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses. Rheumatology (Oxford), 2022, 62(2): 638-646. |
| [35] | Chang YS, Lin CY, Liu TY, Huang CM, Chung CC, Chen YC, Tsai FJ, Chang JG, Chang SJ. Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study. Arthritis Res Ther, 2022, 24(1): 229. |
| [36] | Yang PQ, Pi XN, Marion TN, Wang J, Wang G, Xie Y, Xie D, Liu Y. Gout inheritance in an extended Chinese family analyzed by whole-exome sequencing: A case- report. Medicine (Baltimore), 2020, 99(25): e20057. |
| [37] | Guo Y, Jin J, Zhou ZN, Chen YH, Sun L, Zhang CW, Xia XR. Whole-exome sequencing identifies a novel CPT2 mutation in a pedigree with gout. Front Cell Dev Biol, 2022, 10: 802635. |
| [38] | Huang XF, Sun L, Zhang CW, Zhou ZN, Chen H, Zhang LH, Brown MA, Xia XR. Whole-exome sequencing reveals a rare missense variant in SLC16A9 in a pedigree with early-onset gout. Biomed Res Int, 2020, 2020: 4321419. |
| [39] | Xia XR, Jin J, Chen ZJ, Zhou ZN, Chen H, Zhang CW, Zhang L, Sun L. Unraveling the genetic causes in large pedigrees with gout by whole-exome sequencing. Int J Mol Med, 2020, 45(4): 1047-1058. |
| [40] | Pei F, Pei H, Xia ZH, Xie FS, Su CH. Research progress of epigenetics in hyperuricemia and gout. Prog Physiol Sci, 2019, 50(3): 175-180. |
| [40] | 裴芳, 裴华, 夏中华, 谢福生, 苏春花. 高尿酸血症和痛风的表观遗传学研究进展. 生理科学进展, 2019, 50(3): 175-180. |
| [41] | Stylianou E. Epigenetics of chronic inflammatory diseases. J Inflamm Res, 2019, 12: 1-14. |
| [42] | Li HD, Chen X, Xu JJ, Du XS, Yang Y, Li JJ, Yang XJ, Huang HM, Li XF, Wu MF, Zhang C, Zhang C, Li Z, Wang H, Meng XM, Huang C, Li J. DNMT3b-mediated methylation of ZSWIM3 enhances inflammation in alcohol-induced liver injury via regulating TRAF2- mediated NF-kappaB pathway. Clin Sci (Lond), 2020, 134(14): 1935-1956. |
| [43] | Tseng CC, Wong MC, Liao WT, Chen CJ, Lee SC, Yen JH, Chang SJ. Systemic investigation of promoter-wide methylome and genome variations in gout. Int J Mol Sci, 2020, 21(13): 4702. |
| [44] | Tseng CC, Liao WT, Wong MC, Chen CJ, Lee SC, Yen JH, Chang SJ. Cell lineage-specific methylome and genome alterations in gout. Aging (Albany NY), 2021, 13(3): 3843-3865. |
| [45] | Wang ZM, Zhao Y, Phipps-Green A, Liu-Bryan R, Ceponis A, Boyle DL, Wang J, Merriman TR, Wang W, Terkeltaub R. Differential DNA methylation of networked signaling, transcriptional, innate and adaptive immunity, and osteoclastogenesis genes and pathways in gout. Arthritis Rheumatol, 2020, 72(5): 802-814. |
| [46] | Li B, Chen XY, Jiang YT, Yang Y, Zhong J, Zhou C, Hu HC, Duan SW. CCL2 promoter hypomethylation is associated with gout risk in Chinese Han male population. Immunol Lett, 2017, 190: 15-19. |
| [47] | Yang Y, Chen XY, Hu HC, Jiang YT, Yu H, Dai J, Mao YY, Duan SW. Elevated UMOD methylation level in peripheral blood is associated with gout risk. Sci Rep, 2017, 7(1): 11196. |
| [48] | Zhu ZH, Meng WD, Liu PR, Zhu XX, Liu Y, Zou HJ. DNA hypomethylation of a transcription factor binding site within the promoter of a gout risk gene NRBP1 upregulates its expression by inhibition of TFAP2A binding. Clin Epigenetics, 2017, 9: 99. |
| [49] | Cleophas MCP, Cri?an TO, Klück V, Hoogerbrugge N, Netea-Maier RT, Dinarello CA, Netea MG, Joosten LAB. Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression. Arthritis Res Ther, 2019, 21(1): 50. |
| [50] | Cri?an TO, Cleophas MCP, Oosting M, Lemmers H, Toenhake-Dijkstra H, Netea MG, Jansen TL, Joosten LAB. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis, 2016, 75(4): 755-762. |
| [51] | Jiang H, Ma R, Zou SB, Wang YZ, Li ZQ, Li WP. Reconstruction and analysis of the lncRNA-miRNA- mRNA network based on competitive endogenous RNA reveal functional lncRNAs in rheumatoid arthritis. Mol Biosyst, 2017, 13(6): 1182-1192. |
| [52] | Gezer U, ?zgür E, Cetinkaya M, Isin M, Dalay N. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. Cell Biol Int, 2014, 38(9): 1076-1079. |
| [53] | Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov, 2017, 16(3): 167-179. |
| [54] | Xu YT, Leng YR, Liu MM, Dong RF, Bian J, Yuan LL, Zhang JG, Xia YZ, Kong LY. MicroRNA and long noncoding RNA involvement in gout and prospects for treatment. Int Immunopharmacol, 2020, 87: 106842. |
| [55] | Li X, Pan YY, Li W, Guan PW, You CG. The role of noncoding RNAs in gout. Endocrinology, 2020, 161(11). |
| [56] | Dang WT, Xu D, Xie WG, Zhou JG. Study on the expressions of NLRP3 gene transcript variants in peripheral blood monocytes of primary gout patients. Clin Rheumatol, 2018, 37(9): 2547-2555. |
| [57] | Bai B, Liu YZ, Abudukerimu A, Tian TT, Liang MT, Li R, Sun YP. Key genes associated with pyroptosis in gout and construction of a miRNA-mRNA regulatory network. Cells, 2022, 11(20): 3269. |
| [58] | Li Y, Huang CC, Yang ZG, Wang L, Luo D, Qi L, Li ZC, Huang YQ. Identification of potential biomarkers of gout through competitive endogenous RNA network analysis. Eur J Pharm Sci, 2022, 173: 106180. |
| [59] | Papanagnou P, Stivarou T, Tsironi M. The role of miRNAs in common inflammatory arthropathies: osteoarthritis and gouty arthritis. Biomolecules, 2016, 6(4): 44. |
| [60] | Chen XM, Zhao Y, Wu XD, Wang MJ, Yu H, Lu JJ, Hu YJ, Huang QC, Huang RY, Lu CJ. Novel findings from determination of common expressed plasma exosomal microRNAs in patients with psoriatic arthritis, psoriasis vulgaris, rheumatoid arthritis, and gouty arthritis. Discov Med, 2019, 28(151): 47-68. |
| [61] | Zhou WD, Wang Y, Wu RF, He Y, Su Q, Shi GX. MicroRNA-488 and -920 regulate the production of proinflammatory cytokines in acute gouty arthritis. Arthritis Res Ther, 2017, 19(1): 203. |
| [62] | An LX, Yin FZ. MiR-192-5p suppresses M1 macrophage polarization via epiregulin (EREG) downregulation in gouty arthritis. Tissue Cell, 2021, 73: 101669. |
| [63] | Wang X, Chi JW, Dong BZ, Xu LL, Zhou Y, Huang YJ, Sun SN, Wei FX, Liu YZ, Liu CF, Che K, Lv WS, Chen Y, Wang YG.MiR-223-3p and miR-22-3p inhibit monosodium urate-induced gouty inflammation by targeting NLRP3. Int J Rheum Dis, 2021, 24(4): 599-607. |
| [64] | Lu Y, Fang L, Xu XF, Wu YY, Li JJ. MicroRNA-142-3p facilitates inflammatory response by targeting ZEB2 and activating NF-kappaB signaling in gouty arthritis. Cell Cycle, 2022, 21(8): 805-819. |
| [65] | Li GW, Zhang HH, Ma H, Qu SP, Xing Q, Wang G. MiR-221-5p is involved in the regulation of inflammatory responses in acute gouty arthritis by targeting IL-1beta. Int J Rheum Dis, 2021, 24(3): 335-340. |
| [66] | Wang Y, Dong LP, Liu P, Chen Y, Jia SD, Wang YG. A randomized controlled trial of chuanhutongfeng mixture for the treatment of chronic gouty arthritis by regulating miRNAs. Evid Based Complement Alternat Med, 2019, 2019: 5917269. |
| [67] | Ma T, Liu X, Cen ZF, Xin C, Guo MF, Zou CY, Song WP, Xie R, Wang KL, Zhou H, Zhang J, Wang Z, Bian C, Cui KJ, Li J, Wei YQ, Li J, Zhou XK.MicroRNA-302b negatively regulates IL-1beta production in response to MSU crystals by targeting IRAK4 and EphA2. Arthritis Res Ther, 2018, 20(1): 34. |
| [68] | Zhang QB, Qing YF, Yin CC, Zhou L, Liu XS, Mi QS, Zhou JG. Mice with miR-146a deficiency develop severe gouty arthritis via dysregulation of TRAF 6, IRAK 1 and NALP3 inflammasome. Arthritis Res Ther, 2018, 20(1): 45. |
| [69] | Jin HM, Kim TJ, Choi JH, Kim MJ, Cho YN, Nam KI, Kee SJ, Moon JB, Choi SY, Park DJ, Lee SS, Park YW. MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis. Arthritis Res Ther, 2014, 16(2): R88. |
| [70] | Xu JF, Cao XT. Long noncoding RNAs in the metabolic control of inflammation and immune disorders. Cell Mol Immunol, 2019, 16(1): 1-5. |
| [71] | Chen YG, Satpathy AT, Chang HY. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol, 2017, 18(9): 962-972. |
| [72] | Ye BZ, Wu ZH, Tsui TY, Zhang BF, Su X, Qiu YH, Zheng XT. LncRNA KCNQ1OT1 suppresses the inflammation and proliferation of vascular smooth muscle cells through IκBa in intimal hyperplasia. Mol Ther Nucleic Acids, 2020, 20: 62-72. |
| [73] | Atianand MK, Hu WQ, Satpathy AT, Shen Y, Ricci EP, Alvarez-Dominguez JR, Bhatta A, Schattgen SA, Mcgowan JD, Blin J, Braun JE, Gandhi P, Moore MJ, Chang HY, Lodish HF, Caffrey DR, Fitzgerald KA. A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation. Cell, 2016, 165(7): 1672-1685. |
| [74] | Qing YF, Zheng JX, Tang YP, Dai F, Dong ZR, Zhang QB. LncRNAs Landscape in the patients of primary gout by microarray analysis. PLoS One, 2021, 16(2): e232918. |
| [75] | Zhang XF, Zou Y, Zheng JX, Ji SG, Wen XZ, Ye F, Liu J, Li XY, Lei J, Qiu ML. lncRNA-MM2P downregulates the production of pro-inflammatory cytokines in acute gouty arthritis. Mol Med Rep, 2020, 22(3): 2227-2234. |
| [76] | Xue YY, Liu HJ, Sun ZJ, Xiang T, Shao P. H19 is involved in the regulation of inflammatory responses in acute gouty arthritis by targeting miR-2-3p. Immunol Res, 2022, 70(3): 392-399. |
| [77] | Yang C, Wu D, Gao L, Liu X, Jin YJ, Wang D, Wang TZ, Li XB. Competing endogenous RNA networks in human cancer: hypothesis, validation, and perspectives. Oncotarget, 2016, 7(12): 13479-13490. |
| [78] | Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci, 2018, 19(5): 1310. |
| [79] | Liu YB, Lin LP, Zou R, Wen CY, Wang Z, Lin FQ. MSC-derived exosomes promote proliferation and inhibit apoptosis of chondrocytes via lncRNA-KLF3- AS1/miR-206/GIT1 axis in osteoarthritis. Cell Cycle, 2018, 17(21-22): 2411-2422. |
| [80] | Hu JC, Wu H, Wang DC, Yang ZJ, Dong JJ.LncRNA ANRIL promotes NLRP3 inflammasome activation in uric acid nephropathy through miR-122-5p/BRCC3 axis. Biochimie, 2019, 157: 102-110. |
| [81] | Chen F, Zhang XY, Chen YP, Chai Y, Jiang X, Li HN. Construction of lncRNA-miRNA-mRNA network based on ceRNA mechanism reveals the function of lncRNA in the pathogenesis of gout. J Clin Lab Anal, 2022, 36(6): e24451. |
| [82] | Shu JL, Chen MH, Ya CS, Yang RX, Li FZ. Regulatory role of miRNAs and lncRNAs in gout. Comput Math Methods Med, 2022, 2022: 6513565. |
| [83] | Liu YF, Xing GL, Chen Z, Tu SH. Long non-coding RNA HOTAIR knockdown alleviates gouty arthritis through miR-20b upregulation and NLRP3 downregulation. Cell Cycle, 2021, 20(3): 332-344. |
| [84] | Fang L, Xu XF, Lu Y, Wu YY, Li JJ. Long noncoding RNA SNHG8 accelerates acute gouty arthritis development by upregulating AP3D1 in mice. Bioengineered, 2021, 12(2): 9803-9815. |
| [85] | Lian CF, Sun JL, Guan WJ, Zhang L, Zhang X, Yang L, Hu WL. Circular RNA circHIPK 3 activates macrophage NLRP3 inflammasome and TLR4 pathway in gouty arthritis via sponging miR-561 and miR-192. Inflammation, 2021, 44(5): 2065-2077. |
| [86] | Cifani P, Kentsis A. Towards comprehensive and quantitative proteomics for diagnosis and therapy of human disease. Proteomics, 2017, 17(1-2). |
| [87] | Chen XL, Sun YP, Zhang TT, Shu L, Roepstorff P, Yang FQ. Quantitative proteomics using isobaric labeling: a practical guide. Genomics Proteomics Bioinformatics, 2021, 19(5): 689-706. |
| [88] | Sun GH, Liu J, Wan L, Liu W, Long Y, Bao BX, Zhang Y. Differentially expressed inflammatory proteins in acute gouty arthritis based on protein chip. J Zhejiang Univ Med Sci, 2020, 49(06): 743-749. |
| [88] | 孙广瀚, 刘健, 万磊, 刘维, 龙琰, 鲍丙溪, 张颖. 急性痛风性关节炎致炎蛋白的蛋白质组学研究. 浙江大学学报(医学版), 2020, 49(06): 743-749. |
| [89] | Ying Y, Chen Y, Zhang S, Huang HY, Zou RX, Li XK, Chu ZB, Huang XQ, Peng Y, Gan MZ, Geng BQ, Zhu MY, Ying YY, Huang ZA. Investigation of serum biomarkers in primary gout patients using iTRAQ-based screening. Clin Exp Rheumatol, 2018, 36(5): 791-797. |
| [90] | Chen GQ, Cheng JF, Yu HJ, Huang X, Bao H, Qin L, Wang L, Song YX, Liu XY, Peng A. Quantitative proteomics by iTRAQ-PRM based reveals the new characterization for gout. Proteome Sci, 2021, 19(1): 12. |
| [91] | Huang YK, Liu YQ, Huang QD, Sun SM, Ji ZY, Huang LX, Li Z, Huang XC, Deng WM, Li TW. TMT-based quantitative proteomics analysis of synovial fluid- derived exosomes in inflammatory arthritis. Front Immunol, 2022, 13: 800902. |
| [92] | Li QQ, Wei SS, Wu DH, Wen CP, Zhou J. Urinary metabolomics study of patients with gout using gas chromatography-mass spectrometry. Biomed Res Int, 2018, 2018: 3461572. |
| [93] | Shen X, Wang C, Liang NN, Liu Z, Li XD, Zhu ZJ, Merriman TR, Dalbeth N, Terkeltaub R, Li CG, Yin HY. Serum metabolomics identifies dysregulated pathways and potential metabolic biomarkers for hyperuricemia and gout. Arthritis Rheumatol, 2021, 73(9): 1738-1748. |
| [94] | Li H, Jiang Y, He FC. Recent development of metabonomics and its applications in clinical research. Hereditas (Beijing), 2008, 30(4): 389-399. |
| [94] | 李灏, 姜颖, 贺福初. 代谢组学技术及其在临床研究中的应用. 遗传, 2008, 30(4): 389-399. |
| [95] | Zhang YN, Zhang HZ, Chang D, Guo FC, Pan HZ, Yang YX. Metabolomics approach by (1)H NMR spectroscopy of serum reveals progression axes for asymptomatic hyperuricemia and gout. Arthritis Res Ther, 2018, 20(1): 111. |
| [96] | Zhong Z, Huang YK, Huang QD, Zheng SL, Huang ZX, Deng WM, Li TW. Serum metabolic profiling analysis of gout patients based on UPLC-Q-TOF/MS. Clin Chim Acta, 2021, 515: 52-60. |
| [97] | Luo Y, Wang L, Liu XY, Chen XL, Song YX, Li XH, Jiang CZ, Peng A, Liu JY. Plasma profiling of amino acids distinguishes acute gout from asymptomatic hyperuricemia. Amino Acids, 2018, 50(11): 1539-1548. |
| [98] | Huang YF, Xiao M, Ou JY, Lv Q, Wei QJ, Chen ZN, Wu JL, Tu LD, Jiang YT, Zhang X, Qi J, Qiu ML, Cao SY, Gu JR. Identification of the urine and serum metabolomics signature of gout. Rheumatology (Oxford), 2020, 59(10): 2960-2969. |
| [99] | Luo Y, Wang L, Peng A, Liu JY. Metabolic profiling of human plasma reveals the activation of 5-lipoxygenase in the acute attack of gouty arthritis. Rheumatology (Oxford), 2019, 58(2): 345-351. |
| [100] | Lyu S, Rao Y, Liu P, Yang SL, Chen WY, Yang HJ, Ke SW, Ouyang H, He MZ, Feng YL. Metabolomics analysis reveals four biomarkers associated with the gouty arthritis progression in patients with sequential stages. Semin Arthritis Rheum, 2022, 55: 152022. |
| [101] | Rasheed H, Stamp LK, Dalbeth N, Merriman TR. Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout. Arthritis Res Ther, 2017, 19(1): 161. |
| [102] | Wu YL, Lin ZJ, Li CC, Lin X, Shan SK, Guo B, Zheng MH, Li FX, Yuan LQ, Li ZH. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduct Target Ther, 2023, 8(1): 98. |
| [103] | Chang JG, Tu SJ, Huang CM, Chen YC, Chiang HS, Lee YT, Yen JC, Lin CL, Chung CC, Liu TC, Chang YS. Single-cell RNA sequencing of immune cells in patients with acute gout. Sci Rep, 2022, 12(1): 22130. |
| [104] | Chu YL, Sun SL, Huang YF, Gao Q, Xie XF, Wang P, Li JX, Liang LF, He XH, Jiang YQ, Wang MJ, Yang JH, Chen XM, Zhou CM, Zhao Y, Ding F, Zhang Y, Wu XD, Bai XY, Wu JQ, Wei X, Chen XH, Yue Z, Fang XD, Huang QC, Wang Z, Huang RY. Metagenomic analysis revealed the potential role of gut microbiome in gout. NPJ Biofilms Microbiomes, 2021, 7(1): 66. |
| [105] | Méndez-Salazar EO, Vázquez-Mellado J, Casimiro- Soriguer CS, Dopazo J, ?ubuk C, Zamudio-Cuevas Y, Francisco-Balderas A, Martínez-Flores K, Fernández- Torres J, Lozada-Pérez C, Pineda C, Sánchez-González A, Silveira LH, Burguete-García AI, Orbe-Orihuela C, Lagunas-Martínez A, Vazquez-Gomez A, López-Reyes A, Palacios-González B, Martínez-Nava GA. Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism. Mol Med, 2021, 27(1): 50. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
